Concepedia

Takahiro Seki

TS

Statistics

Publications

15

Citations

1.3K

H-Index

13

Active since

2008

Affiliations

Shionogi (Japan)(Current)

GlaxoSmithKline (United States)

Futaba (Japan)

Research Triangle Park Foundation

Takahiro Seki is an author at Shionogi (Japan) specializing in antiretroviral therapy, antiviral resistance, and virology.

ORCID

Publications per year

2008–2020

15

Publications

15

<i>In Vitro</i>Antiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor

Masanori Kobayashi, Tomokazu Yoshinaga, Takahiro Seki et al. · Antimicrobial Agents and Chemotherapy · 2010 · 377 citations · Full text

, , +17

Dolutegravir (S/GSK1349572) Exhibits Significantly Slower Dissociation than Raltegravir and Elvitegravir from Wild-Type and Integrase Inhibitor-Resistant HIV-1 Integrase-DNA Complexes

Kendra E. Hightower, Ruolan Wang, Felix Deanda et al. · Antimicrobial Agents and Chemotherapy · 2011 · 223 citations

, , +17

Carbamoyl Pyridone HIV-1 Integrase Inhibitors 3. A Diastereomeric Approach to Chiral Nonracemic Tricyclic Ring Systems and the Discovery of Dolutegravir (S/GSK1349572) and (S/GSK1265744)

Brian A. Johns, Takashi Kawasuji, Jason G. Weatherhead et al. · Journal of Medicinal Chemistry · 2013 · 184 citations · Full text

, , +17

Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants

Masanori Kobayashi, Koichiro Nakahara, Takahiro Seki et al. · Antiviral Research · 2008 · 106 citations

, , +9

Antiviral Characteristics of GSK1265744, an HIV Integrase Inhibitor Dosed Orally or by Long-Acting Injection

Tomokazu Yoshinaga, Masanori Kobayashi, Takahiro Seki et al. · Antimicrobial Agents and Chemotherapy · 2014 · 100 citations · Full text

, , +17

1–5 of 15